Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot
→ Esperion got a 15% bump on its stock price $ESPR this morning after the biotech reported that the FDA had said it
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
